Table 3.
LAIV efficacy relative to TIV in active‐controlled pediatric studies
| Study number (reference) | Region | Age range | Number of subjects | Influenza season | Relative efficacy compared with TIV % (95% CI) | |
|---|---|---|---|---|---|---|
| Against matched strains | Against all strains regardless of match | |||||
| MI‐CP111 22 | North America, Europe, Asia, Middle East | 6 to <60 months | 8475 | 2004–2005 | 44·5 (22·4, 60·0) | 54·9 (45·4, 62·9) |
| D153‐P514 20 | Europe, Israel | 6 to <72 months* | 2187 | 2002–2003 | 52·7 (21·6, 72·2) | 52·4 (24·6, 70·5) |
| D153‐P515 21 | Europe, Israel | 6 to <18 years** | 2229 | 2002–2003 | 34·7 (3·9, 56·0) | 31·9 (1·1, 53·5) |
LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.
*The study population consisted of children with a history of recurrent respiratory tract infections.
**The study population consisted of children with stable, medically‐treated asthma. Due to insufficient data, the current US prescribing information states that LAIV should not be administered to any individuals with asthma or children <5 years of age with recurrent wheezing because of the potential for increased risk of wheezing post‐vaccination unless the potential benefit outweighs the potential risk.